Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition

CDK8/19 kinases, which mediate transcriptional reprogramming, have become an active target for cancer drug discovery. Several small-molecule CDK8/19 inhibitors showed in vivo efficacy and two have entered clinical trials, with no significant toxicities reported. However, Clarke et al. (eLife 2016; 5...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Mengqian, Li, Jing, Liang, Jiaxin, Thompson, Zanshé S., Kathrein, Katie, Broude, Eugenia V., Roninson, Igor B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912361/
https://www.ncbi.nlm.nih.gov/pubmed/31717492
http://dx.doi.org/10.3390/cells8111413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912361/
https://www.ncbi.nlm.nih.gov/pubmed/31717492
http://dx.doi.org/10.3390/cells8111413

Ejemplares similares